Whatever the resistance mechanism associated or not with STAT5 signaling, our data suggest that combination treatments with a STAT5 inhibitor might efficiently eliminate resistant CML and AML cells. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.